Jasper Therapeutics- Warrants (24/09/2026) Operating Income

As of the most recent data (June 2026), JSPRW shows a operating income of $-55M. That compares with $-94M in the prior-year period — up 41.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, JSPRW's operating income is now $-55M (was $-94M) — a 41.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Jasper Therapeutics- Warrants (24/09/2026) is outperforming or lagging.

Tracking JSPRW's operating income over time shows whether Jasper Therapeutics- Warrants (24/09/2026) is scaling, shrinking, or reshaping that part of the business. The current reading is $-55M That compares with $-94M in the prior-year period — up 41.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Jasper Therapeutics- Warrants (24/09/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-55M) with ownership activity and broader fundamentals.